NCT06782737Enrolling by invitation
Mediterranean Diet Versus Standard Diet on Candiormetabolic Indicator in Patients With Apnea
Effect of the Mediterranean Type Diet Versus Standard Diet on Cardiometabolic Indicator in Patients With Obstructive Sleep Apnea
Source: ClinicalTrials.gov · Last updated 20 Jan 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Introduction. Worldwide, obstructive sleep apnea is estimated to affect one in seven individuals. Patients with OSA present chronic low-grade inflammation related to arteriosclerosis. The effect of the Mediterranean diet on metabolic risk indicators is still inconclusive in the OSA population. Objective: To evaluate the effect of a Mediterranean diet adapted to the Mexican diet, versus standard nutritional treatment, on metabolic risk indicators in patients with obstructive sleep apnea. Material and methods: Randomized clinical trial in patients with OSA confirmed by polysomnography. Sociodemographic data, pathological and non-pathological history, as well as clinical data will be collected by interview. Patients will be randomly assigned to the group with personalized Mediterranean-type diet adapted to the Mexican diet or standard diet for patients with OSA. At baseline, 6 and 12 months with the patient fasting, glucose levels and lipid profile in venous blood will be measured, as well as carotid artery thickness. Anthropometry and body composition measurements will also be taken, in addition to questionnaires to measure sleep quality, physical exercise and quality of life, as well as to measure dietary adherence with 3-day food records. A descriptive analysis of qualitative variables will be performed with frequencies and percentages; quantitative variables will be presented according to their free or parametric distribution. An X2 will be performed to compare the difference between the proportions of the outcome variables, as well as a Student's t-test or Mann Whitney U test according to their parametric or free distribution. A multivariate analysis will be performed to see the effect of both interventions on the main outcome variables, obesity, dyslipidemia and glycemic control.
- Status (registry)
- Enrolling by invitation
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- First submitted
- 13 Jan 2025
- Start date
- 15 Oct 2024
- Primary completion date
- 13 Dec 2024
- Lead sponsor
- Coordinación de Investigación en Salud, Mexico
- Diseases
- Obesity
- NCT number
- NCT06782737
What you commit to
- Study type: Interventional
- Planned participants: 120
- From 15 Oct 2024 to the primary completion date, 13 Dec 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Treatment with benzodiazepines, antidepressants, anxiolytics and hypnotics.
Other illness
- Chronic kidney disease in substantive treatment of renal function
- Decompensated heart failure
- Cancer
- Neurological disease.
Other
- Anatomical alterations of the nose, oropharynx or maxilla.
- Depression
- Anxiety
- Refractory Dyslipidemia
- Familial Dyslipidemia
- Surgeries in less than 6 months
Who the study is looking for
- Men and women
- Clinical diagnosis of sleep apnea
- Diagnosis of moderate and severe OSA
Age in the registry: 30 years to 70 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Instituto Mexicano del Seguro Social Coordinator of this site? Confirm its status | Mexico City | Mexico | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.